세계의 진단용 심전계/ECG 시장 : 제품별, 리드 유형별, 유형별, 전개/연결별, 최종사용자별, 지역별 - 예측(-2032년)

The global diagnostic electrocardiograph/ECG market is projected to reach USD 15.18 billion by 2032 from USD 9.19 billion in 2025, at a CAGR of 7.4% during the forecast period.

The significant expansion of the geriatric demographic worldwide, coupled with the escalating prevalence of chronic conditions such as diabetes and CVDs, is poised to drive the demand for the diagnostic ECG market. Additionally, the increasing focus on preventive healthcare, coupled with rising healthcare expenditures and improvements in healthcare infrastructure across various regions, also facilitates market growth. Technological advancements in diagnostic ECG devices, the introduction of innovative products, and favorable reimbursement frameworks, along with supportive government policies, are further expected to enhance market dynamics. Investments in healthcare infrastructure and initiatives to improve the accessibility and affordability of diagnostic ECG solutions are also likely to bolster market progression.

The diagnostic ECG devices segment is to grow at the highest CAGR during the forecast period.

The diagnostic ECG market is predominantly driven by devices, which command the largest market share in 2024. This surge is primarily attributed to the rising incidence of CVDs, including coronary artery disease, stroke, and peripheral artery disease. Furthermore, the demand for early and continuous cardiac monitoring among geriatric populations, along with the increasing trend toward remote patient management, significantly underpins this growth trajectory. Recent advancements in device technology, such as miniaturization and enhanced wireless connectivity, are rendering these instruments more efficient, user-centric, and accessible. This evolution enables the provision of cardiac care in both conventional clinical environments and remote settings, thereby improving patient outcomes and optimizing healthcare delivery.

The 12-lead ECG devices segment captured the largest market share, by lead type, in 2024.

Based on lead type, the diagnostic ECG market is segmented into 12, 5, 3, 6, and single lead ECG devices. The 12-lead ECG systems dominate the market due to their ability to deliver comprehensive analysis and a multi-faceted view of cardiac electrical activity through twelve electrode placements-this capability facilitates accurate diagnosis of a range of CVDs, including myocardial infarctions, complex arrhythmias, and ischemic heart disease. Clinicians, particularly in emergency departments, ICUs, and specialized cardiology clinics, heavily depend on the rich data provided by 12-lead ECGs for critical clinical decision-making and timely therapeutic interventions. Furthermore, recent technological advancements, such as portable digital 12-lead ECG devices featuring wireless connectivity and seamless integration with telemedicine platforms, have further solidified the essential role of these systems in the landscape of diagnostic ECG.

The standalone ECG devices segment commanded the largest market share, by deployment/connectivity in 2024.

Based on deployment/ connectivity, the diagnostic ECG market is segmented into standalone, PC-based, and cloud-based ECG devices. Standalone ECG devices accounted for the market share, driven by the rising global prevalence of CVDs that necessitate more accessible and continuous monitoring. The technological advancements have led to the development of compact, precise, and user-friendly devices, coupled with an increasing focus on remote patient monitoring and home-based care. This trend also enhances preventive health management and facilitates self-monitoring of cardiac health outside traditional clinical environments. These devices are instrumental in the early detection of arrhythmias and other cardiac conditions, thus reducing the frequency of hospital visits. They serve as cost-effective alternatives for proactive cardiac health management and can be seamlessly integrated with telemedicine platforms and artificial intelligence for enhanced diagnostic capabilities.

North America accounted for the largest regional share of the diagnostic ECG market in 2024.

The global diagnostic ECG market is segmented into five major regions: North America, Europe, the Asia Pacific, Latin America, and Middle East & Africa. North America is the largest regional market for diagnostic ECG, whereas the Asia Pacific market is estimated to grow at the highest CAGR during the forecast period.

The significant predominance of the North American market can largely be attributed to several interrelated factors. Firstly, there is a rising incidence of CVDs, which has become a pressing public health concern and is driving demand for related healthcare services and products. This increase is further supported by a robust and well-established healthcare infrastructure that efficiently provides medical care and resources to address these health challenges. Additionally, the population in North America enjoys elevated disposable incomes, which allows individuals to prioritize spending on health-related investments, including preventive care and advanced treatment options. This financial capability also supports the adoption of innovative medical technologies and solutions, which are widely accessible throughout the region. The extensive availability of cutting-edge technological advancements in healthcare, including diagnostic tools, treatment modalities, and patient management systems, enhances the overall quality of care and improves health outcomes for patients with CVDs. Together, these factors create a strong environment for market growth and the ongoing evolution of healthcare solutions in North America. Furthermore, the influence of leading industry players such as GE Healthcare, Baxter, and OSI Systems, Inc. is expected to catalyze growth in the diagnostic ECG market within the region.

A breakdown of the primary participants referred to for this report is provided below:

• By Company Type: Tier 1-35%, Tier 2-40%, and Tier 3- 25%
• By Designation: C-level-30%, Director-level-23%, and Other Designations-47%
• By Region: North America-35%, Europe-20%, Asia Pacific-25%, Latin America-13%, and Middle East & Africa-7%

The major players operating in the diagnostic ECG market are GE HealthCare (US), Koninklijke Philips N.V. (Netherlands), Baxter (US), FUKUDA DENSHI (Japan), Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China), NIHON KOHDEN CORPORATION (Japan), OSI Systems, Inc. (US), Bittium (Finland), iRhythm Technologies, Inc. (US), Lepu Medical Technology (Beijing) Co., Ltd. (China), Midmark Corporation (US), BPL Medical Technologies (India), SCHILLER (Switzerland), ACS Diagnostics (US), Allengers (India), and Bionet Co., Ltd. (South Korea).

Research Coverage

This report studies the diagnostic ECG market based on product, lead type, type, deployment/ connectivity, end user, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five major regions (and the respective countries in these regions).

Reasons to Buy the Report

The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to gain a larger market share. Firms purchasing the report could use one or a combination of the following strategies to strengthen their market presence.

This report provides insights on the following points:

• Analysis of Key divers (increasing incidence of lifestyle and cardiovascular diseases, expanding global geriatric population and subsequent surge in heart conditions, development of wireless monitoring and wearable cardiac devices, and growing need for cost-containment across healthcare facilities), restraints (stringent regulatory requirements delaying cardiac device approval and technological limitations of diagnostic ECG devices & software), Opportunities (High growth opportunities in emerging economies and expanding access to advanced cardiac diagnostics with AI and CMS support), Challenges (Limited integration of ECG Systems with electronic health records and accuracy challenges in next-generation ECG monitoring)
• Market Penetration: Comprehensive information on the product portfolios offered by the top players in the diagnostic ECG market
• Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the diagnostic ECG market
• Market Development: Comprehensive information on lucrative emerging regions
• Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the diagnostic ECG market
• Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SCOPE
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS
• 1.6 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Primary sources
    • 2.1.2.2 Key industry insights
    • 2.1.2.3 Breakdown of primaries
• 2.2 MARKET SIZE ESTIMATION OF DIAGNOSTIC ECG PRODUCTS
  • 2.2.1 REVENUE SHARE ANALYSIS (BOTTOM-UP APPROACH)
  • 2.2.2 MNM REPOSITORY ANALYSIS
  • 2.2.3 COMPANY INVESTOR PRESENTATIONS AND PRIMARY INTERVIEWS
  • 2.2.4 TOP-DOWN APPROACH
  • 2.2.5 BOTTOM-UP APPROACH
  • 2.2.6 PRIMARY INTERVIEWS
  • 2.2.7 DEMAND-SIDE APPROACH
  • 2.2.8 VOLUME DATA ANALYSIS
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
  • 2.4.1 STUDY ASSUMPTIONS
  • 2.4.2 RESEARCH LIMITATIONS
• 2.5 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 DIAGNOSTIC ECG MARKET OVERVIEW
• 4.2 NORTH AMERICA: DIAGNOSTIC ECG MARKET SHARE, BY TYPE AND COUNTRY (2024)
• 4.3 DIAGNOSTIC ECG DEVICES MARKET SHARE, BY DEVICE TYPE, 2025 VS. 2032
• 4.4 DIAGNOSTIC ECG MARKET, BY LEAD TYPE, 2025 VS. 2032 (USD MILLION)
• 4.5 DIAGNOSTIC ECG MARKET, BY END USER, 2025 VS. 2032 (USD MILLION)
• 4.6 DIAGNOSTIC ECG MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing incidence of lifestyle and cardiovascular diseases
    • 5.2.1.2 Rapidly expanding global geriatric population and subsequent surge in heart conditions
    • 5.2.1.3 Development of wireless monitoring and wearable cardiac devices
    • 5.2.1.4 Growing need for cost-containment across healthcare facilities
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Stringent regulatory requirements delaying approval of cardiac devices
    • 5.2.2.2 Technological limitations of diagnostic ECG devices and software
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Emerging markets to offer high-growth opportunities
    • 5.2.3.2 Expanding access to advanced cardiac diagnostics with AI and CMS support
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Challenges in integrating ECG systems with Electronic Health Records (EHRs)
    • 5.2.4.2 Accuracy challenges in next-generation ECG monitoring
• 5.3 INDUSTRY TRENDS
  • 5.3.1 MINIATURIZATION AND WEARABLE ECG DEVICES
  • 5.3.2 REMOTE AND HOME-BASED DIAGNOSTICS
  • 5.3.3 HIGH-FIDELITY AND MULTI-LEAD PORTABLE ECGS
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Wearable devices and sensors
    • 5.4.1.2 Integration of Artificial Intelligence (AI)
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Wireless ECG devices
    • 5.4.2.2 Mobile apps integration
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Vital sign monitors
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 THREAT OF NEW ENTRANTS
  • 5.5.2 THREAT OF SUBSTITUTES
  • 5.5.3 BARGAINING POWER OF BUYERS
  • 5.5.4 BARGAINING POWER OF SUPPLIERS
  • 5.5.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.6.3 REGULATORY FRAMEWORK
    • 5.6.3.1 North America
      • 5.6.3.1.1 US
      • 5.6.3.1.2 Canada
    • 5.6.3.2 Europe
    • 5.6.3.3 Asia Pacific
      • 5.6.3.3.1 China
      • 5.6.3.3.2 Japan
      • 5.6.3.3.3 India
    • 5.6.3.4 Latin America
      • 5.6.3.4.1 Brazil
      • 5.6.3.4.2 Mexico
    • 5.6.3.5 Middle East
    • 5.6.3.6 Africa
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS FOR DIAGNOSTIC ECG
  • 5.7.2 JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 TRADE ANALYSIS FOR DIAGNOSTIC ECG PRODUCTS
  • 5.8.2 TRADE DATA FOR HS CODE 901811
    • 5.8.2.1 Import data for HS Code 901811
    • 5.8.2.2 Export data for HS Code 901811
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE, BY KEY PLAYER
    • 5.9.1.1 Average selling price of resting ECG, by key player
    • 5.9.1.2 Average selling price for stress ECG, by key player
    • 5.9.1.3 Average selling price of Holter monitors, by key player
  • 5.9.2 AVERAGE SELLING PRICE, BY REGION
    • 5.9.2.1 Average selling price of resting ECG, stress ECG, and Holter monitors, by region
• 5.10 REIMBURSEMENT SCENARIO
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 KEY BUYING CRITERIA
• 5.13 UNMET NEEDS/END-USER EXPECTATIONS
• 5.14 VALUE CHAIN ANALYSIS
• 5.15 SUPPLY CHAIN ANALYSIS
• 5.16 ECOSYSTEM ANALYSIS
• 5.17 IMPACT OF AI/GEN AI ON DIAGNOSTIC ECG MARKET
  • 5.17.1 INTRODUCTION
  • 5.17.2 MARKET POTENTIAL IN DIAGNOSTIC ECG ECOSYSTEM
  • 5.17.3 AI USE CASES
  • 5.17.4 KEY COMPANIES IMPLEMENTING AI IN DIAGNOSTIC ECG DEVICES
  • 5.17.5 FUTURE OF GEN AI IN DIAGNOSTIC ECG ECOSYSTEM
• 5.18 CASE STUDY ANALYSIS
• 5.19 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.20 IMPACT OF 2025 US TARIFF
  • 5.20.1 INTRODUCTION
  • 5.20.2 KEY TARIFF RATES
  • 5.20.3 PRICE IMPACT ANALYSIS
  • 5.20.4 IMPACT ON COUNTRY/REGION
  • 5.20.5 IMPACT ON END-USER INDUSTRIES
• 5.21 INVESTMENT AND FUNDING SCENARIO

6 DIAGNOSTIC ECG MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 DEVICES
  • 6.2.1 RESTING ECG DEVICES
    • 6.2.1.1 Wide availability of resting ECG devices to support market growth
  • 6.2.2 STRESS ECG DEVICES
    • 6.2.2.1 High cost of stress ECG devices to limit adoption
  • 6.2.3 HOLTER MONITORS
    • 6.2.3.1 Growing demand for continuous monitoring to fuel growth
  • 6.2.4 EVENT MONITORS
    • 6.2.4.1 Increasing outsourcing of monitoring devices to propel market growth
  • 6.2.5 IMPLANTABLE LOOP RECORDERS
    • 6.2.5.1 Introduction of technologically advanced implantable loop recorders to support market growth
  • 6.2.6 MOBILE CARDIAC TELEMETRY DEVICES
    • 6.2.6.1 Increasing demand for cardiac monitoring solutions in home care settings to propel market
  • 6.2.7 SMART ECG MONITORS
    • 6.2.7.1 Rising adoption of smart/wearable ECG monitors
• 6.3 SOFTWARE & SERVICES
  • 6.3.1 SHIFT TOWARD AI-ENABLED ECG SOFTWARE TO SUPPORT GROWTH

7 DIAGNOSTIC ECG MARKET, BY LEAD TYPE

• 7.1 INTRODUCTION
• 7.2 12-LEAD ECG DEVICES
  • 7.2.1 GROWING USE IN PRE-HOSPITAL AND CLINIC SETTINGS TO DRIVE MARKET GROWTH
• 7.3 5-LEAD ECG DEVICES
  • 7.3.1 GROWING IMPORTANCE OF PATIENT MONITORING TO BOOST ADOPTION
• 7.4 3-LEAD ECG DEVICES
  • 7.4.1 VITAL TOOL FOR RHYTHM MONITORING TO SUPPORT MARKET GROWTH
• 7.5 6-LEAD ECG DEVICES
  • 7.5.1 GROWING USE OF 6-LEAD ECG DEVICES IN REMOTE PATIENT MONITORING TO FAVOR MARKET GROWTH
• 7.6 SINGLE-LEAD ECG DEVICES
  • 7.6.1 EASE OF USE FOR DIAGNOSIS AND QUICK RESULTS TO INCREASE USE OF SINGLE-LEAD ECG DEVICES
• 7.7 OTHER ECG LEAD DEVICES

8 DIAGNOSTIC ECG MARKET, BY TYPE

• 8.1 INTRODUCTION
• 8.2 PORTABLE 138 8.2.1 CONVENIENCE AND ACCESSIBILITY OF PORTABLE ECG DEVICES TO ENHANCE EARLY CARDIAC SCREENING
• 8.3 WEARABLE
  • 8.3.1 RISING DEMAND FOR CONTINUOUS HEART MONITORING IN FITNESS AND CHRONIC DISEASE MANAGEMENT
• 8.4 IMPLANTABLE 142 8.4.1 HIGH DIAGNOSTIC YIELD FOR ELUSIVE CARDIAC CONDITIONS WITH LONG-TERM MONITORING

9 DIAGNOSTIC ECG MARKET, BY DEPLOYMENT/CONNECTIVITY

• 9.1 INTRODUCTION
• 9.2 STANDALONE ECG DEVICES
  • 9.2.1 WIDESPREAD ADOPTION OF STANDALONE ECG DEVICES DUE TO OPERATIONAL SIMPLICITY
• 9.3 PC-BASED ECG DEVICES
  • 9.3.1 GROWING USE FOR ADVANCED ECG DIAGNOSTICS AND INTEGRATION TO SUPPORT REMOTE CARDIAC CARE
• 9.4 CLOUD-BASED ECG DEVICES
  • 9.4.1 ACCELERATED GROWTH OF CLOUD-BASED ECG SOLUTIONS TO SUPPORT REMOTE CARDIAC CARE

10 DIAGNOSTIC ECG MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 HOSPITALS
  • 10.2.1 INCREASING UTILIZATION OF ECG DEVICES IN HOSPITALS TO ACCELERATE MARKET GROWTH
• 10.3 PRIMARY CARE CENTERS
  • 10.3.1 WIDENING ACCESS TO ECG DIAGNOSTICS IN PRIMARY CARE CENTERS TO BOOST MARKET PENETRATION
• 10.4 CARDIAC CENTERS
  • 10.4.1 SPECIALIZED ECG APPLICATIONS IN CARDIAC CENTERS TO DRIVE DEMAND FOR ADVANCED DEVICES
• 10.5 AMBULATORY SURGICAL CENTERS
  • 10.5.1 GROWING NEED FOR PRE-OPERATIVE CARDIAC SCREENING IN ASCS TO INFLUENCE MARKET DEMAND
• 10.6 HOME CARE SETTINGS
  • 10.6.1 RISING PREFERENCE FOR REMOTE MONITORING FUELS ECG DEVICE USAGE IN HOME CARE
• 10.7 URGENT CARE SETTINGS
  • 10.7.1 INTEGRATION OF DIAGNOSTIC ECG IN URGENT CARE SETTINGS FOR TIMELY CARDIAC EVALUATIONS TO FUEL MARKET DEMAND
• 10.8 OTHER END USERS
  • 10.8.1 DIVERSE ECG APPLICATIONS ACROSS NURSING HOMES, RETAIL CLINICS, SPORTS MEDICINE & RESEARCH TO INFLUENCE MARKET DEMAND

11 DIAGNOSTIC ECG MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 11.2.2 US
    • 11.2.2.1 US to command largest share in diagnostic ECG market
  • 11.2.3 CANADA
    • 11.2.3.1 Growing adoption of digital diagnostic ECG systems to drive market growth
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 11.3.2 GERMANY
    • 11.3.2.1 High healthcare spending to propel market growth
  • 11.3.3 FRANCE
    • 11.3.3.1 Government support for e-Health to propel market
  • 11.3.4 UK
    • 11.3.4.1 Rising demand for home-based smart ECG devices to support market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Growing focus on improvements in patient care to drive market
  • 11.3.6 SPAIN
    • 11.3.6.1 Rising geriatric population to support market growth in Spain
  • 11.3.7 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 11.4.2 JAPAN
    • 11.4.2.1 High healthcare expenditure and favorable reimbursement and insurance coverage to support market growth in Japan
  • 11.4.3 CHINA
    • 11.4.3.1 Government support for infrastructural improvement to drive market growth
  • 11.4.4 INDIA
    • 11.4.4.1 Increasing cardiac disease burden intensifies demand for ECG diagnostics
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Increased patient volume and favorable government initiatives to drive market
  • 11.4.6 SOUTH KOREA
    • 11.4.6.1 Rising geriatric population to propel market growth
  • 11.4.7 MALAYSIA
    • 11.4.7.1 Increasing CVD burden and national digital health initiatives driving ECG adoption
  • 11.4.8 THAILAND
    • 11.4.8.1 National cardiac screening programs and smart hospital investments driving ECG adoption in Thailand
  • 11.4.9 INDONESIA
    • 11.4.9.1 Rising cardiac disease burden and public health digitalization efforts to drive ECG device uptake in Indonesia
  • 11.4.10 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 11.5.2 BRAZIL
    • 11.5.2.1 Improving access to diagnostic services to drive growth
  • 11.5.3 MEXICO
    • 11.5.3.1 Rising heart disease to drive market growth
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 11.6.2.1.1 Prevalence of CVDs boosting ECG adoption in Saudi Arabia
    • 11.6.2.2 United Arab Emirates (UAE)
      • 11.6.2.2.1 National CVD screening programs and digital health strategies driving market
    • 11.6.2.3 Rest of GCC Countries
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 INTRODUCTION
• 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN DIAGNOSTIC ECG MARKET
• 12.3 REVENUE SHARE ANALYSIS (2022-2024)
• 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.4.1 RANKING OF KEY PLAYERS
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY PRODUCT FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Product footprint
    • 12.5.5.4 Lead type footprint
    • 12.5.5.5 Type footprint
    • 12.5.5.6 Deployment/Connectivity footprint
• 12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
    • 12.6.5.1 Detailed list of key startups/SME players
    • 12.6.5.2 Competitive benchmarking of key startups/SME players
• 12.7 BRAND/PRODUCT COMPARISON
• 12.8 DIAGNOSTIC ECG MARKET: COMPANY VALUATION & FINANCIAL METRICS
  • 12.8.1 FINANCIAL METRICS
  • 12.8.2 COMPANY VALUATION
• 12.9 COMPETITIVE SCENARIO
  • 12.9.1 PRODUCT LAUNCHES & APPROVALS
  • 12.9.2 DEALS
  • 12.9.3 EXPANSIONS
  • 12.9.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 KONINKLIJKE PHILIPS N.V.
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products/Services/Solutions offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product/Service launches
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Other developments
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Key strengths/Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 GE HEALTHCARE
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Deals
      • 13.1.2.3.2 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Key strengths/Right to win
      • 13.1.2.4.2 Strategic choice
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 MEDTRONIC
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 MnM view
      • 13.1.3.3.1 Right to win
      • 13.1.3.3.2 Strategic choices
      • 13.1.3.3.3 Weaknesses and competitive threats
  • 13.1.4 BOSTON SCIENTIFIC CORPORATION
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 MnM view
      • 13.1.4.3.1 Right to win
      • 13.1.4.3.2 Strategic choices
      • 13.1.4.3.3 Weaknesses and competitive threats
  • 13.1.5 ABBOTT LABORATORIES
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product launches
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Key strengths
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses & competitive threats
  • 13.1.6 BAXTER (HILL-ROM HOLDINGS, INC.)
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 MnM view
      • 13.1.6.3.1 Key strengths/Right to win
      • 13.1.6.3.2 Strategic choices
      • 13.1.6.3.3 Weaknesses & competitive threats
  • 13.1.7 FUKUDA DENSHI
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 MnM view
      • 13.1.7.3.1 Key strengths
      • 13.1.7.3.2 Strategic choices
      • 13.1.7.3.3 Weaknesses & competitive threats
  • 13.1.8 SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
    • 13.1.8.3 MnM view
      • 13.1.8.3.1 Key strengths
      • 13.1.8.3.2 Strategic choices
      • 13.1.8.3.3 Weaknesses & competitive threats
  • 13.1.9 NIHON KOHDEN CORPORATION
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
  • 13.1.10 OSI SYSTEMS, INC.
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
    • 13.1.10.3 Recent developments
      • 13.1.10.3.1 Expansions
  • 13.1.11 BITTIUM
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
  • 13.1.12 IRHYTHM TECHNOLOGIES, INC.
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
    • 13.1.12.3 Recent developments
      • 13.1.12.3.1 Product launches and approvals
      • 13.1.12.3.2 Deals
  • 13.1.13 LEPU MEDICAL TECHNOLOGY (BEIJING) CO., LTD.
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches and approvals
      • 13.1.13.3.2 Other developments
  • 13.1.14 MIDMARK CORPORATION
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Product launches
  • 13.1.15 BPL MEDICAL TECHNOLOGIES
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Expansions
      • 13.1.15.3.2 Other developments
  • 13.1.16 SCHILLER
    • 13.1.16.1 Business overview
    • 13.1.16.2 Products offered
    • 13.1.16.3 Recent developments
      • 13.1.16.3.1 Product launches
      • 13.1.16.3.2 Other developments
  • 13.1.17 ACS DIAGNOSTICS
    • 13.1.17.1 Business overview
    • 13.1.17.2 Products offered
  • 13.1.18 ALLENGERS
    • 13.1.18.1 Business overview
    • 13.1.18.2 Products offered
  • 13.1.19 BIONET CO., LTD.
    • 13.1.19.1 Business overview
    • 13.1.19.2 Products offered
    • 13.1.19.3 Recent developments
      • 13.1.19.3.1 Other developments
• 13.2 OTHER PLAYERS
  • 13.2.1 EDAN INSTRUMENTS, INC.
  • 13.2.2 QINGDAO MEDITECH EQUIPMENT CO., LTD.
  • 13.2.3 CARDIAC INSIGHT, INC.
  • 13.2.4 ALIVECOR, INC.
  • 13.2.5 VITALCONNECT
  • 13.2.6 BTL
  • 13.2.7 BORSAM MEDICAL
  • 13.2.8 NASIFF ASSOCIATES, INC.
  • 13.2.9 VECTRACOR, INC.
  • 13.2.10 BIOMEDICAL INSTRUMENTS CO., LTD.
  • 13.2.11 LIFESIGNALS

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS